Predict your next investment

Venture Capital
ktventuregroup.com

See what CB Insights has to offer

Investments

27

Portfolio Exits

8

Funds

2

About KT Venture Group LLC

KT Venture Group is a venture capital firm investing in startups in the semiconductor and related high-technology microelectronics industries. They consider non-semiconductor markets where KT's core competencies in image processing, inspection and measurement, and yield-management technologies can add significant value.Within the semiconductor space, this means a focus on process technologies, integration & optimization, infrastructure solutions and subsystems & suppliers. In the non-semiconductor arena, the firm evaluates: (1) Biomedical Equipment & Devices, (2) Biotechnology Instrumentation & Metrology, (3) Security Equipment & Devices, (4) Display Technology, (5) Nanotechnology, (6) Photonics Manufacturing, (7) MEMS Manufacturing.

KT Venture Group LLC Headquarter Location

160 Rio Robles Building D

San Jose, California, 95134-1809,

United States

408.875.9800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest KT Venture Group LLC News

BioNanomatrix Closes $23.3M Series B

Mar 18, 2011

BioNanomatrix Closes $23.3M Series B March 18, 2011 BioNanomatrix Inc., a developer of nanoscale, single-molecule imaging and analysis platforms, has raised $23.3 million in Series B financing. Domain Associates led the round, with participation from new investor Gund Investment Corporation and existing shareholders Battelle Ventures, Innovation Valley Partners and KT Venture Group joining the round. Domain Associates has offices in Princeton, N.J., and San Diego. PRESS RELEASE BioNanomatrix, Inc, a developer of nanoscale, single-molecule imaging and analysis platforms designed to dramatically reduce the time and cost needed to analyze the genome, has closed a $23.3-million Series B round of equity financing. Domain Associates, based in Princeton, N.J., and San Diego, Calif., led the round, with new investor Gund Investment Corporation and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture Group joining the round. “The Series B financing comes at a pivotal time for the company, as we advance toward commercialization of our unique nanoAnalyzer platform for whole genome analysis,” said R. Erik Holmlin, newly elected president and chief executive officer of BioNanomatrix. Holmlin noted that BioNanomatrix introduced the nanoAnalyzer 1000 System at the 2010 annual meeting of the American Society of Human Genetics last November and said that the company “has already placed a number of systems with early-access users.” “BioNanomatrix has made impressive progress in developing and refining its platform technology and testing the nanoAnalyzer in collaboration with leading researchers in the genomics field,” said Domain Associates Partner Brian K. Halak, PhD., who joins the company’s Board of Directors. “This capital infusion enables BioNanomatrix to establish a strong West Coast presence that will provide additional business opportunities and the ability to recruit from a talent base that has established this industry,” Dr. Halak continued. “Looking ahead,” he said, “we are confident that the affordability, speed and simplicity of the nanoAnalyzer technology will make the routine use of genetic information feasible in broad-ranging applications, including molecular diagnostics, personalized medicine and biomedical research.” About BioNanomatrix Named in 2010 as one of 50 companies to watch by Medical Device and Diagnostic Industry, BioNanomatrix is developing and commercializing technologies for analysis of large biological molecules, such as nucleic acids, which are vital to life science research, clinical diagnostic applications and development of new therapeutics. This technology is designed to dramatically reduce the time and complexity to analyze the genome and provide additional information, including structural variation data, which is not easily addressed with current methods. The company’s products will provide users with the means to perform single-molecule analyses on minute biological samples that are essentially unattainable, too impractical or too costly to achieve using current technology. The company’s current development efforts include a NIST-ATP-funded project to sequence the human genome at a cost of $100, as well as support from the National Institutes of Health. For more information, visit www.bionanomatrix.com © 2015 Buyouts Insider / Argosy Group LLC

KT Venture Group LLC Investments

27 Investments

KT Venture Group LLC has made 27 investments. Their latest investment was in Nikola Labs as part of their Seed VC - III on July 7, 2019.

CBI Logo

KT Venture Group LLC Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/13/2019

Seed VC - III

Nikola Labs

$4M

Yes

3

3/17/2011

Series B

BioNano Genomics

$23.3M

No

1

2/11/2011

Unattributed VC

Tela Innovations

$4.75M

No

1

7/16/2010

Series D

Subscribe to see more

$99M

Subscribe to see more

0

7/8/2010

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/13/2019

3/17/2011

2/11/2011

7/16/2010

7/8/2010

Round

Seed VC - III

Series B

Unattributed VC

Series D

Series C

Company

Nikola Labs

BioNano Genomics

Tela Innovations

Subscribe to see more

Subscribe to see more

Amount

$4M

$23.3M

$4.75M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

1

0

0

KT Venture Group LLC Portfolio Exits

8 Portfolio Exits

KT Venture Group LLC has 8 portfolio exits. Their latest portfolio exit was INNOViON on August 12, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/12/2020

Acquired

$99M

3

8/21/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2014

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

4/23/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/1/2010

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/12/2020

8/21/2018

12/19/2014

4/23/2014

7/1/2010

Exit

Acquired

IPO

Acq - Fin

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

KT Venture Group LLC Fund History

2 Fund Histories

KT Venture Group LLC has 2 funds, including KT Venture Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/30/2007

KT Venture Fund II

Early-Stage Venture Capital

Closed

$35M

1

10/12/2000

KT Venture Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/30/2007

10/12/2000

Fund

KT Venture Fund II

KT Venture Fund I

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$35M

$99M

Sources

1

10

KT Venture Group LLC Team

4 Team Members

KT Venture Group LLC has 4 team members, including current Managing Director, Stefano Concina.

Name

Work History

Title

Status

Stefano Concina

Managing Director

Current

Robert Lee

General Partner

Current

Mahesh Krishnamurthy

Idanta Partners

General Partner

Former

Peter Wolken

Diamondhead Ventures, and AllegisCyber Capital

General Partner

Former

Name

Stefano Concina

Robert Lee

Mahesh Krishnamurthy

Peter Wolken

Work History

Idanta Partners

Diamondhead Ventures, and AllegisCyber Capital

Title

Managing Director

General Partner

General Partner

General Partner

Status

Current

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.